Importantly, overexpression of YAP/TAZ correlates with poor prognosis for patients with hepatocellular carcinoma (HCC), colon cancer, esophageal squamous cell carcinoma, late-stage ovarian cancer, non-small-cell lung cancer, and breast tumor (Wang et al., 2010; Chen et al., 2012; Harvey et al., 2013; Xia et al., 2014). The gene discussed is YAP1; the disease is hepatocellular carcinoma.